Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Christophe Weber
Pharma
Takeda looks to put generic Vyvanse woes in the rearview
The gap between Vyvanse generic sales declines and growth from new products is narrowing, Takeda said on its third-quarter 2025 earnings call.
Zoey Becker
Jan 29, 2026 1:21pm
With Weber retiring in 2026, Takeda names Kim as its next CEO
Jan 30, 2025 9:35am
Daiichi-Merck, Wegovy, Takeda CEO—Fierce Pharma Asia
Jun 28, 2024 8:40am
Takeda focuses on Qdenga as it braces for Vyvanse generics
Jul 27, 2023 1:38pm
Takeda expects patent expirations to weigh on earnings
May 12, 2023 11:10am
Takeda expands manufacturing in preparation for Qdenga launch
Jan 10, 2023 10:17am
